Brief: Evaxion’S Ai Technology Identifies Cancer Vaccine Targets Associated With Longer Progression-Free Survival Of Melanoma Patients
03/06/2023 22:03
June 3 (Reuters) - Evaxion Biotech A/S EVAX.O :
* EVAXION’S AI TECHNOLOGY IDENTIFIES CANCER VACCINE TARGETS
ASSOCIATED WITH LONGER PROGRESSION-FREE SURVIVAL OF MELANOMA
PATIENTS IN THE EVX-01 PHASE 1 CLINICAL TRIAL
* CLINICAL TRIAL OF PERSONALIZED CANCER VACCINE EVX-01 MET
ITS
PRIMARY ENDPOINTS OF SAFETY AND TOLERABILITY
* PHASE 1 TRIAL SUCCESSFULLY MET PRIMARY ENDPOINTS FOR
SAFETY AND
TOLERABILITY OF EVX-01 IN METASTATIC MELANOMA PATIENTS
Source text for Eikon: ID:nGNX7992Yx
Further company coverage: EVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma